GENE ONLINE|News &
Opinion
Blog

2023-10-24| Asia-Pacific

AMS BioteQ Makes Debut at Medical Japan 2023: Bringing Innovative Healthcare into New Horizons

by Oscar Wu
Share To

Medical Japan Tokyo 2023 was held grandly from October 11 to 13, gathering medical professionals, manufacturers, medical institutions and research units from around the world. AMS BioteQ Co., Ltd. made its first appearance in the exhibition and became one of the spotlight. Founded in 2018, AMS BioteQ (TPE: 6864) specializes in the microbial field, particularly in solving the problem of antibiotic resistance. Utilizing its patented biotechnological process, ExtrO™, the company has successfully developed several technologies and products, including a novel natural antibacterial material called MediAce®, which could promote wound healing process.

Medical Japan is a leading international healthcare exhibition held in Japan, covering various sectors such as medical devices, medical equipment, elderly care, and the pharmaceutical industry. The exhibition serves as a significant gateway for entering the Japanese and broader Asian healthcare markets. It attracts a diverse range of visitors, including professionals in medical devices, medical supplies, and elderly care, as well as importers and distributors. The exhibition is composed of six specialized sub-exhibitions and offers a platform for active and effective business interactions.

AMS BioteQ’s CEO, Dr. George Tsai

Related article: AMS BioteQ Touts Antimicrobial Dressings for Chronic Wound Infections

Innovative Moist Treatment, Yielding Novel Wound Healing Process

Product on-site trial received enthusiastic response

Moist treatment creates a conducive environment for accelerated healing by facilitating autolytic debridement, reducing pain, and promoting collagen synthesis and keratinocyte formation. This approach outperforms traditional dressings like gauze and bandages, speeding up the healing process by 3-5 times. Particularly effective for diabetic foot ulcers, moist treatment helps regulate the extracellular matrix, thereby aiding wound closure.

Leveraging this concept, AMS BioteQ has developed a new series of hydrophilic dressings called SIPSIPTM, crafted from eco-friendly materials. These dressings excel in anti-adhesion, anti-scarring, and tissue regeneration. The SIPSIPTM series is available in three specialized types: “Complex”, “Pro”, and “Foam”, each engineered with patented, non-allergenic, and highly absorbent properties. “Complex” offers comprehensive wound care and scar prevention, “Pro” is tailored for sensitive skin with superior moisturizing capabilities, and “Foam” is designed for optimal absorbency and minimal wound adhesion.

A key innovation in the SIPSIPTM series is the use of gelatin as the primary ingredient. It absorbs wound exudate to form a protective gel layer, maintaining a moist wound environment. This feature not only ensures biocompatibility but also offers a cost-effective solution. The dressings have distinct pores with an average size between 60 and 70 μm and a porosity ranging from 60% to 67%. According to EN-13726-1 standards, these dressings can absorb approximately 25-35 times their own weight in liquid, making them highly effective in wound management.

AMS-2140, an Innovative Anti-Dengue Candidate

Beyond its cutting-edge dressing technology, AMS BioteQ is also set to introduce AMS-2140, a groundbreaking anti-dengue candidate in this event. CEO Dr. George Tsai secured the extraction methodology from National Chung Hsing University, allowing the company to source AMS-2140 from botanicals. Notably, this compound has demonstrated the ability to neutralize the dengue virus while maintaining non-toxicity to animal models, positioning AMS BioteQ as a potential leader in Dengue therapeutics.

Captivating Global Interest across Multiple Sectors with Unique Technology

AMS BioteQ team took a group photo at the exhibition

Throughout the exhibition, in addition to introducing the company basic information, R&D Supervisor Dr. Ying-Ting Yeh and Deputy R&D Manager Dr. Caleb Tang had offered in-depth presentations on SIPSIPTM Pro and AMS-2140. AMS BioteQ initially estimated to receive 500 visitors, but the actual number exceeded 1,000, with an effective visitor ratio near 50%. In addition to local Japanese visitors, who made up 70% of the total, the remaining 30% came from China, Hong Kong, Macau, Korea and Southeast Asian countries like Thailand, Singapore, Malaysia, the Philippines, and Indonesia. About 10% of the visitors were from Europe, the Middle East, and Africa, including countries like Belgium, Latvia, the Netherlands, Romania, Algeria, Saudi Arabia, and South Africa. The visitor demographic was diverse, including import-export traders, medical equipment agents, staff from hospitals and long-term care institutions, as well as many decision-makers.

Actively apply for regulatory permissions and gradually expand international research cooperation

In this exhibition, AMS BioteQ unveiled its innovative SIPSIPTM series of medical dressings, with plans to submit medical device license applications to both the FDA and TFDA by the end of 2023, targeting revenue growth for 2024. Accompanied by two experts from their R&D department, the company offered detailed insights into their promising new products, including the SIPSIPTM series and AMS-2140. This exhibition served as a pivotal platform for AMS BioteQ, as their cutting-edge products and technologies have not only opened up a new direction in healthcare but also garnered significant attention from industry professionals and investors alike.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Author
Related Post
Breaking Boundaries in Wound Care, AMS BioteQ at Medical Japan 2023
2023-10-03
Breaking Boundaries in Wound Care, AMS BioteQ at Medical Japan 2023
2023-10-02
AMS BioteQ Touts Antimicrobial Dressings for Chronic Wound Infections
2022-04-13
LATEST
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
Oncology’s New Drugs on the Horizon (I): Cancer Immunotherapy and Targeted Therapy
2024-04-12
Vertex Pharmaceuticals Makes $4.9 Billion Bet on Kidney Disease Treatment through Alpine Immune Acquisition
2024-04-11
Bayer Signs New Partnership with Google Cloud, Joining Hands for AI Solutions for Radiologists
2024-04-10
Pharmacogenomics (PGx) Shaping the Dynamic APAC Regions
2024-04-10
Connecting Biotech Ecosystems: Success of Los Angeles Event Sets Stage for APAC-US Collaboration
2024-04-10
Innovating Prostate Cancer Care: SYNC-T, Proteogenomics, and Culturally Tailored Education at AACR 2024
2024-04-10
EVENT
Scroll to Top